Advertisement

The Indian Journal of Pediatrics

, Volume 86, Issue 5, pp 403–405 | Cite as

Neuroblastoma in a Developing Country: Miles to Go

  • Jagdish Prasad Meena
  • Aditya Kumar GuptaEmail author
Editorial Commentary

Neuroblastoma (NB) is the most common intraabdominal and extracranial solid tumor in children, accounting for approximately 8% to 10% of all childhood malignancies. As per the ‘Indian Council of Medical Research (ICMR), National Cancer Registry Program’, the relative proportion of NB (and ganglioneuroblastoma) in children (0–14 y), in seven hospital-based cancer registries across India varied from 2.4% to 7.5%. Neuroblastoma is the most common malignancy diagnosed during infancy. It can arise from anywhere along the sympathetic chain and usually presents as a mass arising in the neck, mediastinum, abdomen or pelvis. Neuroblastoma is a disease of early childhood with approximately 90% of patients presenting before the age of five years. In infants, these tumors may regress spontaneously, or they may mature into a benign ganglioneuroma. Neuroblastoma in older children is usually unresectable or is metastatic at presentation, and the overall prognosis is poor [1, 2].

In low-and...

Notes

Compliance with Ethical Standards

Conflict of Interest

None.

References

  1. 1.
    Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams and Wilkins; 2016. p. 772–97.Google Scholar
  2. 2.
    Indian Council of Medical Research. Consolidated Report of Hospital Based Cancer Registries 2007–11. Available at: http://www.ncrpindia.org/ALL_NCRP_REPORTS/HBCR_REPORT_2007_2011/ALL_CONTENT/Main.htm. Accessed 4 Mar 2019.
  3. 3.
    Kitonyi GW, Macharia WM, Mwanda OW, Pamnani R. Clinico-pathologic characteristics and treatment outcomes in children with neuroblastoma at the Kenyatta National Hospital. Nairobi East Afr Med J. 2009;86:S39–46.Google Scholar
  4. 4.
    Hesseling PB, Ankone K, Wessels G, Schneider JW, Plessis D, Moore L. Neuroblastoma in southern Africa: epidemiological features, prognostic factors and outcome. Ann Trop Paediatr. 1999;19:357–63.CrossRefGoogle Scholar
  5. 5.
    Parise IZ, Haddad BR, Cavalli LR, et al. Neuroblastoma in southern Brazil: an 11-year study. J Pediatr Hematol Oncol. 2006;28:82–7.CrossRefGoogle Scholar
  6. 6.
    Li K, Dong K, Gao J. YaoW, Xiao X, Zheng S. Neuroblastoma management in Chinese children. J Investig Surg. 2012;25:86–92.CrossRefGoogle Scholar
  7. 7.
    Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24:65–86.CrossRefGoogle Scholar
  8. 8.
    Erdelyi DJ, Elliott M, Phillips B. Urine catecholamines in paediatrics. Arch Dis Child Educ Pract Ed. 2011;96:107–11.CrossRefGoogle Scholar
  9. 9.
    Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21:2486–91.CrossRefGoogle Scholar
  10. 10.
    Kushner BH, Yeung HW, Larson SM, et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol. 2001;19:3397–405.CrossRefGoogle Scholar
  11. 11.
    Scanga DR, Martin WH, Delbeke D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med. 2004;29:86–90.CrossRefGoogle Scholar
  12. 12.
    Parikh NS, Howard SC, Chantada G, et al. SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015;62:1305–16.CrossRefGoogle Scholar
  13. 13.
    Bansal D, Marwaha RK, Trehan A, Rao KL, Gupta V. Profile and outcome of neuroblastoma with conventional chemotherapy in children older than one year: a 15 y experience. Indian Pediatr. 2008;45:135–9.Google Scholar
  14. 14.
    Agarwala S, Mandelia A, Bakhshi S, et al. Neuroblastoma: outcome over a 14 y period from a tertiary care referral centre in India. J Pediatr Surg. 2014;49:1280–5.CrossRefGoogle Scholar
  15. 15.
    Kusumakumari P, Ajithkumar TV, Hariharan S, et al. Intensive chemotherapy in children with stage IV neuroblastoma. Indian J Pediatr. 1999;66:867–72.CrossRefGoogle Scholar
  16. 16.
    Kulkarni KP, Marwaha RK. Outcome of neuroblastoma in India. Indian J Pediatr. 2013;80:832–7.CrossRefGoogle Scholar
  17. 17.
    Radhakrishnan V, Raja A, Dhanushkodi M, Ganesan TS, Selvaluxmy G, Sagar TG. Real world experience of treating neuroblastoma: experience from a tertiary cancer centre in India. Indian J Pediatr. 2019.  https://doi.org/10.1007/s12098-018-2834-6.

Copyright information

© Dr. K C Chaudhuri Foundation 2019

Authors and Affiliations

  1. 1.Division of Pediatric Oncology, Department of PediatricsAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations